Delivering Complex Parenteral Formulations

Progress in delivery science, manufacturing technologies, and commercialization are playing critical roles in advancing the development of complex parenteral drug formulations for new drug substances having a variety of formulation challenges. Unique formulation strategies and solutions are being investigated to extend the release of target peptides, proteins, nucleic acids, and small molecules for systemic, local, or cellular delivery. Pharmaceutical Technology will hold a live educational webcast, “Complex Parenteral Formulations for the Delivery of Peptides, Proteins, Nucleic Acids and Small Molecules,” on Thursday Nov. 21 from 10:00 to 11:00 AM EST, to examine the delivery science and product development of complex parenteral formulations.

The webcast will examine formulation design and fabrication technologies used to make extended-release parenteral formulations for systematic and local delivery of peptides, proteins, and small molecules. Dosage forms to be discussed will include bioabsorbable microparticles and implants. The webcast also will examine siRNA drug delivery by exploring advances in achieving human proof of concept for RNA interference and defining opportunities to develop nucleic acid-based medicines. Delivery approaches and related clinical applications will be examined for lipid nanoparticles, targeted conjugates, and polymer conjugates.

Panelists for the webcast will be Thomas Tice, PhD, senior director of global technical marketing with Evonik Corporation, and Mark Tracy, PhD, president of BioConsulting LLC. Dr. Tice is internationally recognized for research in drug delivery and has lectured on the topic throughout the world. His specialties include microencapsulation, implants, controlled release and medical applications of bioabsorbable polymers. In particular, he is known for his accomplishments involving injectable, extended-release microparticles made with bioabsorbable lactide/glycolide polymers designed to release pharmaceuticals. He led the team that developed the first commercial, injectable microparticle product, which was a one-month LHRH formulation indicated for the treatment of prostate cancer (Decapeptyl® SR) and that is still on the market today. Dr. Tice also serves on the United States Pharmacopeia General Chapters-Dosage Forms Expert Committee. Dr. Tracy has played a key role in successfully bringing nine new protein, peptide, nucleic acid, and small-molecule-based medicines to the clinic utilizing the latest advances in drug delivery technology, including several that were commercialized. He is a past president of the Controlled Release Society and is a fellow of the American Institute for Medical and Biological Engineering.

Viewers will be able to ask questions of the panelists in a dedicated Q&A session during the live webcast. Additional information, including how to register for the live webcast, “Complex Parenteral Formulations for the Delivery of Peptides, Proteins, Nucleic Acids and Small Molecules,” on Thursday Nov. 21 from 10:00 to 11:00 EST may be found here. The webcast will also be available on November 28 from 10:00-11:00 AM Central European Time (CET).